Extended-release quetiapine is commonly used for treatment-resistant depression, but a new study reveals patients receiving esketmanine nasal spray are 54% more likely to reach remission at 8 weeks.
“Over 32 weeks of follow-up, the percentage of patients with remission, the percentage of patients with a treatment response, and the change in the MADRS score from baseline favored esketamine nasal spray.”
“Among employed adults with TRD, esketamine nasal spray treatment was associated with significantly larger improvements in WPL and related costs compared to quetiapine extended-release treatment.”
Janssen to Showcase New Insights and Commitment to Accelerating Hope and Healing for Serious Mental Illness at Psych Congress 2023 marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson will showcase data from its neuropsychiatry portfolio at Psych Congress 2023. The.